Asked by: Daniel Kawczynski (Conservative - Shrewsbury and Atcham)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment he has made of the potential merits of funding UK-based studies of the (a) use of the Bacillus Calmette-Guérin vaccine to prevent bovine tuberculosis, (b) period of effectiveness of that vaccine and (c) benefits of that vaccine to the beef industry.
Answered by Mark Spencer - Minister of State (Department for Environment, Food and Rural Affairs)
Developing a deployable cattle bovine TB vaccine is one of the government’s top priorities. Field trials have been taking place in England and Wales since 2021, following a major breakthrough by government scientists in the development of a new DIVA skin test to Detect Infected among Vaccinated Animals. The aim of these trials is to gather information to enable both the CattleBCG (Bacillus Calmette-Guérin) vaccine and the new DIVA skin test to be authorised for use and recognised internationally.
CattleBCG stimulates a protective immune response in vaccinated cattle. In the Animal and Plant Health Agency (APHA)’s experimental challenge model vaccinated animals display a range of protection and demonstrate a 12 month duration of immunity. The extent of disease reduction from CattleBCG depends on many factors including severity of exposure to bTB and herd immunity. Establishing the true level of protection afforded by vaccines is only possible by monitoring and assessing performance after licensing and routine use in the population vaccinated. When combined with existing disease control measures, we are confident that widespread vaccination will help to further reduce the incidence of bTB and its impact on cattle farms in England.
We continue to work in partnership with stakeholders, alongside colleagues in Scotland and Wales, to assess how this potential new tool could be deployed in the future and provide the greatest possible benefit to our herds for generations to come.
Information on the development of a bovine TB cattle vaccine can be found on the TB Hub at https://tbhub.co.uk/resources/frequently-asked-questions/development-of-a-deployable-tuberculosis-vaccine-for-cattle/.
Asked by: Yasmin Qureshi (Labour - Bolton South East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential merits of each Integrated care systems having a (a) specialist allergy nurse and (b) dietitian.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The majority of services for people living with allergies are commissioned locally through integrated care boards (ICBs), which are best placed to commission services according to local need. Specialised allergy services are provided for patients with severe and complex allergic conditions, or those who have common allergic conditions for which conventional management has failed and for whom specified specialist treatments are required. In 2023/24, these services are jointly commissioned by NHS England Specialised Commissioning and the ICBs, in line with the published Specialist Allergy Service Specification.
There is an established Clinical Reference Group (CRG), which is responsible for providing national clinical advice and leadership for specialised immunology and allergy services. The CRG uses its expertise to advise NHS England on the best ways to provide specialised services. This includes developing national standards in the form of service specifications and policies. The CRG commenced a review of the current service specification in May 2023, which is expected to be complete by summer 2024. The outcome of the service specification review will be an updated specification which references up-to-date guidance and takes into account the latest evidence base, to clearly define the standards of care for commissioned specialised services.
To help promote awareness of allergies, the National Institute for Health and Care Excellence (NICE) has published guidance on a range of allergy conditions, including food allergy in under 19-year-olds, anaphylaxis, and drug allergy. The NICE promotes its guidance via its website, newsletters, and other media.
To support clinicians in the implementation of clear care pathways, the NICE website has guidance to support diagnosis and treatment of a range of allergy conditions, including how to identify allergies and when to refer to specialist care, and how to ensure allergies are recorded in their medical records. The NICE website also provides primary care practitioners with access to clinical knowledge summaries outlining the current evidence base and practical guidance on a range of skin conditions.
Asked by: Yasmin Qureshi (Labour - Bolton South East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve allergy awareness in health care settings.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The majority of services for people living with allergies are commissioned locally through integrated care boards (ICBs), which are best placed to commission services according to local need. Specialised allergy services are provided for patients with severe and complex allergic conditions, or those who have common allergic conditions for which conventional management has failed and for whom specified specialist treatments are required. In 2023/24, these services are jointly commissioned by NHS England Specialised Commissioning and the ICBs, in line with the published Specialist Allergy Service Specification.
There is an established Clinical Reference Group (CRG), which is responsible for providing national clinical advice and leadership for specialised immunology and allergy services. The CRG uses its expertise to advise NHS England on the best ways to provide specialised services. This includes developing national standards in the form of service specifications and policies. The CRG commenced a review of the current service specification in May 2023, which is expected to be complete by summer 2024. The outcome of the service specification review will be an updated specification which references up-to-date guidance and takes into account the latest evidence base, to clearly define the standards of care for commissioned specialised services.
To help promote awareness of allergies, the National Institute for Health and Care Excellence (NICE) has published guidance on a range of allergy conditions, including food allergy in under 19-year-olds, anaphylaxis, and drug allergy. The NICE promotes its guidance via its website, newsletters, and other media.
To support clinicians in the implementation of clear care pathways, the NICE website has guidance to support diagnosis and treatment of a range of allergy conditions, including how to identify allergies and when to refer to specialist care, and how to ensure allergies are recorded in their medical records. The NICE website also provides primary care practitioners with access to clinical knowledge summaries outlining the current evidence base and practical guidance on a range of skin conditions.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of drugs available within the NHS to treat (a) epidermolysis bullosa and (b) other inflammatory skin conditions.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) makes independent, evidence-based recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits.
Currently, there is one product licensed specifically for epidermolysis bullosa, Filsuvez gel, which contains birch bark extract. The NICE recommends birch bark extract as a clinically and cost effective use of NHS resources, and the NHS is legally required to fund it in line with the NICE’s recommendations. Other healthcare products are also used in the care of epidermolysis bullosa patients. There are a number of licensed and NICE recommended treatments for other inflammatory skin conditions that are now routinely available for NHS patients.
Asked by: Grahame Morris (Labour - Easington)
Question to the Ministry of Justice:
To ask the Secretary of State for Justice, pursuant to the Answer of 28 February 2024 to Question 15436, whether assaults by razor are counted under (a) knife/blade or (b) other sharp instrument.
Answered by Edward Argar - Minister of State (Ministry of Justice)
Assaults by razor should be counted in knife/blade, as the definition is “an object with a sharp edge that is designed to puncture, chop, slice or scrape surfaces, skin, material”. However, as there is no formal reference to razors, we expect that some may also be in the ‘other sharp instrument’ category, defined as “objects or instruments which are able to cut, prick, cause injury and / or infection e.g.,needle, broken glass” and the ‘other’ category.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of (a) mould and (b) damp on the long-term health of social housing tenants.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
In September 2023 the Department of Health and Social Care, jointly with the Department of Levelling Up, Housing and Communities, and the UK Health Security Agency, published Understanding and addressing the health risks of damp and mould in the home, which is available on GOV.UK website. This guidance sets out the health risks of damp and mould, and the steps social and private landlords should take to address these issues.
The guidance indicates that damp and mould in the home may present a significant health risk to social housing tenants and can contribute to the development and worsening of respiratory conditions. Damp and mould can also affect the eyes and skin and contribute to fungal infections, especially in people with weakened immune systems.
Asked by: Neil Hudson (Conservative - Penrith and The Border)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce waiting times for (a) urgent and (b) non-urgent referrals of patients from General Practice to hospitals in (i) Cumbria and (ii) England.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Cutting waiting lists is one of this Prime Minister’s top priorities. We are making good progress on tackling the longest waits, and ensuring patients get the care they need when they need it. That is why we have published the elective recovery plan, which sets clear ambitions to eliminate long waits for planned National Health Service treatment. The overall vision is to eradicate waits of longer than a year for elective care by March 2025.
To facilitate this across elective services, we are increasing activity, with plans to spend more than £8 billion from 2022/23 to 2024/25. This will expand capacity though creating a new network of community diagnostic centres, including three in Cumbria, and maximising all available independent sector capacity. We are managing demand through specialised advice in primary care and giving patients more control over where they receive their care. We are also increasing productivity through transforming outpatient services, developing new surgical hubs to increase theatre productivity, and working actively with trusts to support and challenge their performance.
The latest published figures show that the 62-day backlog has fallen 36% since its peak in the pandemic. The NHS introduced the Faster Diagnosis Standard (FDS), which aims to ensure patients have cancer diagnosed or ruled out within 28 days of urgent suspected cancer referral from a general practice or screening services. Latest FDS performance was at 71.9% in November 2023 against the national standard of 75%.
To achieve the FDS target, NHS England are streamlining cancer pathways, including timed cancer pathways, to speed up diagnosis in the three key cancer pathways: lower gastrointestinal, prostate, and skin.
We are also implementing non symptom specific pathways for patients who present with non-specific symptoms, or combinations of non-specific symptoms, that can indicate several different cancers.
Asked by: Olivia Blake (Labour - Sheffield, Hallam)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of maternity and neonatal safety improvement schemes on mitigating the effects of inequalities in perinatal deaths.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
In March 2023, NHS England published its three-year delivery plan for maternity and neonatal services. This sets out how the National Health Service will make maternity and neonatal care more equitable, as well as safer and more personalised.
The three-year delivery plan is based on evidence, including the impact on inequalities where available, and wide consultation. NHS England is tracking the impact on maternity and neonatal outcomes based on ethnicity and deprivation.
A central ambition of the delivery plan is to reduce inequalities in access, experience and outcomes for women and babies. This is being delivered through the implementation of Local Maternity and Neonatal Systems equity and equality action plans and advocating a proportionate universalism approach, alongside targeted service models designed to reduce inequalities, including enhanced midwifery continuity of carer and culturally sensitive genetics services for high need areas.
NHS England is also providing training and resources for all maternity and neonatal staff, so they can deliver culturally competent and sensitive care. This includes access to cultural competence training, developed in partnership with the Royal College of Midwives, and provision of clinical training aids to support care for women and babies with black or dark skin. In November 2023, NHS England offered £50,000 funding to each NHS England regional team in England to implement ethnic minority workforce training to upskill staff and promote more equitable experience for service users.
In January 2024, the NHS Race and Health Observatory launched the Learning and Action Network in partnership with the Institute for Healthcare Improvement and the Health Foundation. The Learning and Action Network will utilise an anti-racism approach to quality improvement to drive clinical transformation and enable system-wide change. It will work with nine healthcare systems to improve maternal and neonatal health outcomes.
Additionally, the Care Quality Commission’s (CQC’s) national maternity inspection programme, which completed in December 2023, looked at how services are addressing inequalities in maternity care through a safety and leadership lens. The CQC will be reporting on their findings from the inspection programme later this year and will include findings relating to inequalities.
Asked by: Olivia Blake (Labour - Sheffield, Hallam)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that maternity and neonatal safety improvement schemes include a focus on mitigating the effects of inequalities.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
In March 2023, NHS England published its three-year delivery plan for maternity and neonatal services. This sets out how the National Health Service will make maternity and neonatal care more equitable, as well as safer and more personalised.
The three-year delivery plan is based on evidence, including the impact on inequalities where available, and wide consultation. NHS England is tracking the impact on maternity and neonatal outcomes based on ethnicity and deprivation.
A central ambition of the delivery plan is to reduce inequalities in access, experience and outcomes for women and babies. This is being delivered through the implementation of Local Maternity and Neonatal Systems equity and equality action plans and advocating a proportionate universalism approach, alongside targeted service models designed to reduce inequalities, including enhanced midwifery continuity of carer and culturally sensitive genetics services for high need areas.
NHS England is also providing training and resources for all maternity and neonatal staff, so they can deliver culturally competent and sensitive care. This includes access to cultural competence training, developed in partnership with the Royal College of Midwives, and provision of clinical training aids to support care for women and babies with black or dark skin. In November 2023, NHS England offered £50,000 funding to each NHS England regional team in England to implement ethnic minority workforce training to upskill staff and promote more equitable experience for service users.
In January 2024, the NHS Race and Health Observatory launched the Learning and Action Network in partnership with the Institute for Healthcare Improvement and the Health Foundation. The Learning and Action Network will utilise an anti-racism approach to quality improvement to drive clinical transformation and enable system-wide change. It will work with nine healthcare systems to improve maternal and neonatal health outcomes.
Additionally, the Care Quality Commission’s (CQC’s) national maternity inspection programme, which completed in December 2023, looked at how services are addressing inequalities in maternity care through a safety and leadership lens. The CQC will be reporting on their findings from the inspection programme later this year and will include findings relating to inequalities.
Asked by: Catherine West (Labour - Hornsey and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made with the Chancellor of the Exchequer of the potential impact of removing VAT from factor 30+ sunscreen on the level of incidence of skin cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Whilst the Department has not made a specific assessment, under the current VAT rules, sun protection products are subject to the standard rate of VAT. High-factor sunscreen is on the National Health Service prescription list for certain conditions and therefore is provided free of VAT when dispensed by a pharmacist. While HM Treasury keeps all taxes under review, there are no plans to make changes. Representations on changes to the VAT system will be considered through the normal fiscal event process.